CN111685322A - Composition for promoting gastric digestion and health-care product and application thereof - Google Patents
Composition for promoting gastric digestion and health-care product and application thereof Download PDFInfo
- Publication number
- CN111685322A CN111685322A CN202010558699.9A CN202010558699A CN111685322A CN 111685322 A CN111685322 A CN 111685322A CN 202010558699 A CN202010558699 A CN 202010558699A CN 111685322 A CN111685322 A CN 111685322A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- dried
- fried
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000029087 digestion Effects 0.000 title claims abstract description 34
- 230000001737 promoting effect Effects 0.000 title claims abstract description 34
- 230000002496 gastric effect Effects 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 46
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 25
- 241000132012 Atractylodes Species 0.000 claims abstract description 17
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 17
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 17
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 16
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 16
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 16
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 16
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 16
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 16
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 16
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 16
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 16
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 16
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 15
- 235000008397 ginger Nutrition 0.000 claims abstract description 15
- 241000756943 Codonopsis Species 0.000 claims abstract description 4
- 239000002002 slurry Substances 0.000 claims abstract description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 26
- 238000002156 mixing Methods 0.000 claims description 19
- 239000000047 product Substances 0.000 claims description 18
- 241001092040 Crataegus Species 0.000 claims description 15
- 238000005303 weighing Methods 0.000 claims description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 241000234314 Zingiber Species 0.000 claims description 13
- 229960004543 anhydrous citric acid Drugs 0.000 claims description 13
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 12
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 12
- 229960004998 acesulfame potassium Drugs 0.000 claims description 12
- 239000000619 acesulfame-K Substances 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 10
- 235000019202 steviosides Nutrition 0.000 claims description 10
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 229940013618 stevioside Drugs 0.000 claims description 9
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 229920000858 Cyclodextrin Polymers 0.000 claims description 7
- 239000001116 FEMA 4028 Substances 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 7
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 7
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 7
- 229960004853 betadex Drugs 0.000 claims description 7
- 229960000913 crospovidone Drugs 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 7
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 7
- 239000000377 silicon dioxide Substances 0.000 claims description 7
- 235000012239 silicon dioxide Nutrition 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 6
- 235000010439 isomalt Nutrition 0.000 claims description 6
- 239000000905 isomalt Substances 0.000 claims description 6
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000000967 suction filtration Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 238000007599 discharging Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000001125 extrusion Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims 2
- 235000013305 food Nutrition 0.000 abstract description 29
- 210000002784 stomach Anatomy 0.000 abstract description 19
- 239000003814 drug Substances 0.000 abstract description 14
- 238000002474 experimental method Methods 0.000 abstract description 10
- 206010010774 Constipation Diseases 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 5
- 230000014759 maintenance of location Effects 0.000 abstract description 4
- 244000273928 Zingiber officinale Species 0.000 abstract description 2
- 230000001143 conditioned effect Effects 0.000 abstract description 2
- 230000000968 intestinal effect Effects 0.000 abstract description 2
- 210000000936 intestine Anatomy 0.000 abstract description 2
- 230000009044 synergistic interaction Effects 0.000 abstract description 2
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 29
- 238000012360 testing method Methods 0.000 description 24
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 18
- 210000000952 spleen Anatomy 0.000 description 18
- 102000057297 Pepsin A Human genes 0.000 description 15
- 108090000284 Pepsin A Proteins 0.000 description 15
- 229940111202 pepsin Drugs 0.000 description 15
- 241000700159 Rattus Species 0.000 description 13
- 239000013642 negative control Substances 0.000 description 13
- 201000006549 dyspepsia Diseases 0.000 description 11
- 230000037406 food intake Effects 0.000 description 9
- 235000012631 food intake Nutrition 0.000 description 9
- 210000000813 small intestine Anatomy 0.000 description 9
- 235000019786 weight gain Nutrition 0.000 description 9
- 239000000976 ink Substances 0.000 description 8
- 102000038379 digestive enzymes Human genes 0.000 description 7
- 108091007734 digestive enzymes Proteins 0.000 description 7
- 210000004051 gastric juice Anatomy 0.000 description 7
- 230000004584 weight gain Effects 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 description 5
- 206010000060 Abdominal distension Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 235000019605 sweet taste sensations Nutrition 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 239000004382 Amylase Substances 0.000 description 3
- 108010065511 Amylases Proteins 0.000 description 3
- 102000013142 Amylases Human genes 0.000 description 3
- 241000092665 Atractylodes macrocephala Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 235000019418 amylase Nutrition 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000001952 enzyme assay Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- -1 lignan glycosides Chemical class 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010006298 Breast pain Diseases 0.000 description 2
- 241000675108 Citrus tangerina Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 235000017159 Crataegus pinnatifida Nutrition 0.000 description 2
- 241000657480 Crataegus pinnatifida Species 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000006662 Mastodynia Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000019525 fullness Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 235000019633 pungent taste Nutrition 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- FNXIDRUUVHQLHR-UHFFFAOYSA-N C(C)(=O)OS(=O)(C1=CC=C(C=C1)N)=O.[K] Chemical compound C(C)(=O)OS(=O)(C1=CC=C(C=C1)N)=O.[K] FNXIDRUUVHQLHR-UHFFFAOYSA-N 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010059186 Early satiety Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241000235343 Saccharomycetales Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004383 Steviol glycoside Substances 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000010227 chenpi Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000003866 digestant Substances 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical compound C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000009924 shiquandabu Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229930182488 steviol glycoside Natural products 0.000 description 1
- 235000019411 steviol glycoside Nutrition 0.000 description 1
- 150000008144 steviol glycosides Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition for promoting gastric digestion, and a health-care product and application thereof. The composition comprises the following components: radix Codonopsis, parched Atractylodis rhizoma, parched fructus Hordei Germinatus, pericarpium Citri Tangerinae, Zingiberis rhizoma, brewing yeast powder, and fructus crataegi slurry powder. The invention selects the codonopsis pilosula, the fried bighead atractylodes rhizome, the fried malt, the dried orange peel, the dried ginger, the brewing yeast powder and the hawthorn pulp powder as raw materials, has homology of medicine and food and has high edible safety. Experiments prove that the components have synergistic interaction, the stomach digestion is effectively promoted, the intestinal flora is adjusted, the constipation problem caused by food retention is improved, and the intestines and the stomach are simultaneously conditioned.
Description
Technical Field
The invention belongs to the field of health care products, and particularly relates to a composition for promoting gastric digestion, a health care product and application thereof.
Background
Modern people have irregular diet, greasy taste, coldness, acridity and too fast, are compensated to drink, overeat, have high working and living pressure, and are easy to cause discomfort symptoms such as gastrectasia, abdominal distension, indigestion and the like due to environmental factors, genetic factors and the like. The uncomfortable symptoms are called Functional Dyspepsia (FD) in modern medicine, and belong to the categories of epigastric pain, fullness, epigastric upset and the like in traditional Chinese medicine.
FD refers to digestive dysfunction symptoms derived from gastroduodenal diseases, i.e., persistent or recurrent epigastric pain, abdominal distension, early satiety, belching, anorexia, acid regurgitation, nausea, vomiting, etc., and can exclude organic, systemic, metabolic diseases that may explain the symptoms, and the course of disease is generally defined as more than one month or more than twelve weeks in a month, which is a common functional gastrointestinal disease. In recent years, the rate of FD pathogenic population is increased year by year, and the incidence rate of FD population in Europe and America is 19% -41%, and the average incidence rate is 32%; the content of the active ingredients in the domestic is 18-45 percent, and the active ingredients account for 20-40 percent of the digestion clinic. FD not only affects the quality of life of the patient, but also constitutes a considerable medical expense.
Western medicine FD is mainly used for symptomatic treatment, such as promotion of gastric motility, protection of gastric mucosa, inhibition of gastric acid secretion, helicobacter pylori resistance and the like, and the Western medicine treatment effect is not obvious because FD causes and pathogenesis are not clear and clinical symptoms are repeated. In recent years, a great number of experimental researches are carried out by combining the basic theory of traditional Chinese medicine with clinical practice of a plurality of medical students, and the result proves that the basic formula of the traditional Chinese medicine has obvious curative effect of FD addition and subtraction treatment and is obviously superior to the treatment of western medicines.
Disclosure of Invention
In view of the above, the primary object of the present invention is to provide a composition for promoting gastric digestion, wherein the components in the composition have synergistic effects and have an effective effect of promoting gastric digestion.
The invention is realized by the following technical scheme;
a composition for promoting gastric digestion comprising the components: radix Codonopsis, parched Atractylodis rhizoma, parched fructus Hordei Germinatus, pericarpium Citri Tangerinae, Zingiberis rhizoma, brewing yeast powder, and fructus crataegi slurry powder.
The raw materials of the invention are reported as follows:
codonopsis pilosula: codonopsis pilosula (Codonopsispilosula) is one of the commonly used clinical tonifying herbs. Codonopsis pilosula belongs to Campanulaceae, has sweet taste and mild nature, enters spleen and lung meridians, and has effects of invigorating spleen and replenishing qi, promoting fluid production and regulating stomach. Dangshen is indicated for spleen-lung deficiency, qi and blood deficiency, tiredness and weakness in clinic because it is sweet and neutral but not dry and greasy, and commonly used prescriptions are sijunzi decoction, eight-treasure decoction, and shiquan dabu pill, etc. Radix Codonopsis contains various chemical components, such as terpenes, sugar and glycosides, steroids, flavonoids, lignan glycosides, coumarins, alkaloids, volatile oil, organic acids, amino acids, etc. The codonopsis pilosula is one of effective traditional Chinese medicines for regulating the functions of the spleen and the stomach, and has multiple effects on the digestive system.
Frying the bighead atractylodes rhizome: the white atractylodes rhizome is the dried rhizome of white atractylodes rhizome (Atractyly-lodes macrocephala Koidz) of Compositae, is mainly used for tonifying spleen qi clinically, has warm nature, sweet taste and slight pungent and bitter taste, has the functions of strengthening spleen and tonifying qi, eliminating dampness and promoting diuresis, stopping sweating and preventing miscarriage, and is used for treating diseases such as spleen deficiency, anorexia, abdominal distention and diarrhea, phlegm and fluid retention, dizzy palpitation, edema, spontaneous perspiration, threatened abortion and the like. Atractylodis rhizoma mainly contains volatile oil, atractylenolide, polysaccharide, and glycosides. Atractylodes macrocephala lactone I, II and III are anti-inflammatory effective components, and Atractylodes macrocephala volatile oil and Atractylodes macrocephala lactone III have anticancer effect.
And (3) malt frying: the fructus Hordei Germinatus is prepared from mature fruit of Gramineae fructus Hordei vulgaris (Hordeum vulgare L.) by germinating and drying, and has sweet taste and spleen and stomach meridian tropism; has effects in promoting qi circulation, resolving food stagnation, invigorating spleen, stimulating appetite, invigorating qi, tonifying deficiency, and relieving breast distention; it can be used for treating dyspepsia, abdominal pain, spleen deficiency, anorexia, breast pain, and breast pain. From Ben Cao gang mu, it is said that it is effective in promoting digestion, regulating the middle warmer, breaking cold air, removing heart and abdominal distention. In the treatise of the herb Property, it is said that it "digests food, breaks cold air, and removes fullness in the heart and abdomen". Malt is a commonly used group digestant used to promote digestion of starchy foods. The fructus Hordei Germinatus contains amylase, invertase, esterase, protease, phospholipid, vitamin B, vitamin C, maltose, glucose, and maltodextrins. Starch is decomposed into maltose and dextrin under the action of enzyme, the dextrin can be decomposed into maltose by the enzyme, the maltose is beneficial to absorption by organisms, and the amylase contained in the malt is one of the main components for promoting digestion.
Dried orange peel: the pericarpium Citri Tangerinae is dry mature pericarp of Rutaceae plant fructus Citri Tangerinae (Citrus reticulate Blanco) and its cultivar, is pungent, bitter and warm in taste, enters spleen and lung channels, and has effects of regulating qi-flowing, invigorating spleen, eliminating dampness and eliminating phlegm. The functional value of tangerine peel is recorded in the Ming dynasty Li Shizhen Ben Cao gang mu, which records the functions of eliminating phlegm, lowering qi, promoting the production of body fluid, stimulating the appetite, strengthening the spleen and stomach, and detoxifying and soothing the nerves. Ming dynasty plum-Shizhenyun: "tonics are tonifying, purgatives are purging, ascending and descending. Spleen is the mother of original qi and lung is the label for qi absorption, so orange peel is the herb for qi system of two meridians, but it can tonify and purge ascending and descending along with the recipe. In China, the Chinese medicine holds that the orange peel is better as the orange peel is older, so the orange peel is called as the tangerine peel. "Chenpi" is mainly used for treating digestive system and respiratory system diseases, is the most commonly used medicine for treating digestive tract diseases such as esophagus, stomach and duodenum, etc., and can be used for treating abdominal distension, belch, vomiting, constipation or diarrhea, etc. The pericarpium Citri Tangerinae mainly contains volatile oil, flavonoids, polysaccharides, organic amines and microelements, and has effects of increasing blood pressure, resisting platelet aggregation, resisting oxidation, resisting aging, resisting bacteria, resisting allergy, resisting tumor, killing parasite, and promoting digestion.
Dried ginger: zingiberis rhizoma is dried rhizome of Zingiber officinale Roscoe of Zingiberaceae, and has pungent taste and mild nature. It enters lung, spleen and stomach meridians. Has the effects of relieving exterior syndrome, dispelling cold, warming middle energizer, relieving vomiting, warming lung, relieving cough, and removing toxic substance. Can be used for treating wind-cold type common cold, spleen and stomach cold syndrome, stomach cold emesis, cough due to lung cold, and fish and crab toxin relieving.
Brewing yeast powder: saccharomyces cerevisiae, also known as baker's yeast or budding yeast. Saccharomyces cerevisiae is the most widely related yeast to human, not only because it is traditionally used for making bread, steamed bread and other food and brewing wine, but also as a eukaryotic model organism in modern molecular and cellular biology, and its function is equivalent to prokaryotic model organism Escherichia coli. Saccharomyces cerevisiae is the most commonly used biological species in fermentation. The saccharomyces cerevisiae is a concentrated bank of natural nutrients and is rich in protein, a plurality of B vitamins, dietary fiber and a plurality of mineral elements. The brewing yeast powder mainly acts in stomach, duodenum, small intestine and cecum to promote digestion.
Hawthorn pulp powder: the fructus crataegi is dry mature fruit of Crataegus pinnatifida Bgevar majorn.E.Br. or Crataegus pinnatifida Bge. of Rosaceae, and has mild nature, sour and sweet taste, and can enter spleen, stomach and liver channels. Has effects of resolving food stagnation, invigorating stomach, activating qi-flowing, removing blood stasis, eliminating turbid pathogen and reducing blood lipid, and can be used for treating meat food stagnation, gastric cavity distention, dysentery abdominal pain, blood stasis amenorrhea, puerperal blood stasis, heart and abdomen stabbing pain, thoracic obstruction, cardialgia, hernia pain, and hyperlipidemia. The charred fructus crataegi has enhanced effect in promoting digestion and resolving food stagnation, and can be used for treating food stagnation and dysentery. The fructus crataegi mainly contains cellulose, tannin, triterpenes, flavonoids, flavane and its polymer, organic acids, and steroids. Has effects in regulating blood lipid, protecting liver, lowering blood pressure, promoting digestion, tonifying heart, resisting oxidation, resisting tumor, and inhibiting bacteria.
Fructus crataegi contains VC and VB2Carrot and various organic acids, and can increase the secretion of digestive enzyme in stomach, enhance the activity of enzyme and promote digestion. The hawthorn contains pepsin agonist which can enhance the activity of protease; in addition, the food also contains amylase, which can enhance the activity of pancreatic lipase, and achieve the effects of promoting digestion, stimulating appetite and promoting appetite.
The invention takes radix codonopsitis, fried bighead atractylodes rhizome, fried malt, dried orange peel, dried ginger, brewing yeast powder and hawthorn pulp powder as raw materials, wherein the radix codonopsitis is a monarch drug for tonifying middle-jiao and Qi, strengthening spleen and nourishing stomach; stir-baked white atractylodes rhizome, rhizoma atractylodis macrocephalae is used for removing dampness and promoting digestion, tonifying qi and promoting diuresis, and mediating middle energizer is used as the minister; the hawthorn pulp powder is used for eliminating food stagnation, especially eliminating food stagnation caused by greasy meat; the roasted malt eliminates rice and food retention, the dried orange peel regulates qi and stomach, and the dried orange peel also serves as a guiding drug; the brewing yeast powder can promote digestion and eliminate stagnation, and can be used for enhancing the digestion promoting effect of the product under the synergistic effect with other components. The medicines are combined to play the effects of strengthening spleen and stomach, removing food retention and removing food stagnation.
As a preferred embodiment, the composition for promoting gastric digestion comprises the following components in parts by weight: 10-40 parts of codonopsis pilosula, 10-40 parts of fried bighead atractylodes rhizome, 10-40 parts of fried malt, 10-40 parts of dried orange peel, 2-10 parts of dried ginger, 5-20 parts of brewing yeast powder and 5-20 parts of hawthorn pulp powder.
In a preferred embodiment, the composition for promoting gastric digestion is prepared from the following components in parts by weight: 20 parts of codonopsis pilosula, 15 parts of fried bighead atractylodes rhizome, 15 parts of fried malt, 15 parts of dried orange peel, 7 parts of dried ginger, 5 parts of brewing yeast powder and 5-20 parts of hawthorn pulp powder.
The invention also provides application of the composition in preparing a health-care product for promoting gastric digestion.
The invention also provides a health-care product for promoting gastric digestion, which is prepared from the composition and acceptable auxiliary materials in the health-care product according to the conventional method in the field.
The dosage form of the health care product can be tablets, capsules, powder, granules, pills or oral liquid and the like, and preferably tablets.
Suitable excipients may be isomalt, D-mannitol, microcrystalline cellulose, crospovidone, silicon dioxide, magnesium stearate, anhydrous citric acid, acesulfame potassium, steviol glycosides and the like in amounts conventional in the art.
As a preferred embodiment of the present invention, the tablet comprises the following components in parts by weight:
10-40 parts of codonopsis pilosula, 10-40 parts of fried bighead atractylodes rhizome, 10-40 parts of fried malt, 10-40 parts of dried orange peel, 2-10 parts of dried ginger, 5-20 parts of brewing yeast powder, 5-20 parts of hawthorn pulp powder, 5-20 parts of beta-cyclodextrin, 20-50 parts of isomalt, 2-15 parts of mannitol, 2-15 parts of microcrystalline cellulose, 2-10 parts of anhydrous citric acid, 0.1-2 parts of acesulfame potassium, 0.1-1 part of stevioside, 2-10 parts of crospovidone, 1-5 parts of silicon dioxide and 1-5 parts of magnesium stearate.
The invention also provides a preparation method of the tablet, which comprises the following steps:
(1) weighing: weighing the medicinal materials of codonopsis pilosula, dried orange peel, fried bighead atractylodes rhizome, fried malt and dried ginger according to the formula ratio for later use; crushing the anhydrous citric acid, screening the crushed anhydrous citric acid by a 60-mesh screen, and weighing for later use; sieving potassium acetylsulfanilate and stevioside by 40 meshes, and weighing for later use; other materials are agglomerated and pass through a 40-mesh screen;
(2) extracting and concentrating: adding weighed medicinal materials into an extraction tank, extracting with water for 1-2 times, filtering the extractive solution, and mixing
Filtering the filtrate, taking the extracted filtrate, performing suction filtration, and recovering and concentrating the filtrate after suction filtration to obtain a concentrated solution;
(3) spray drying and granulating: adding beta-cyclodextrin into the concentrated solution, mixing, heating, stirring, spray drying, and collecting
Spraying dry powder, and passing the sprayed dry powder through a 20-mesh screen in an extrusion manner to obtain spray-dried particles;
(4) total mixing: the anhydrous citric acid, the acesulfame potassium, the stevioside, the crospovidone and the spray drying are added according to the formula amount
Adding granule, brewing yeast powder, fructus crataegi powder, isomalt, mannitol, microcrystalline cellulose, and silicon dioxide into a mixer, mixing for 20-30min, adding magnesium stearate, mixing for 5-10min, mixing, discharging, and tabletting.
In the preparation method of the tablet, beta-cyclodextrin is used during spray drying, so that the peculiar smell of the traditional Chinese medicine can be embedded, and in addition, the hawthorn pulp powder is added to ensure that the taste of the final product is better.
Compared with the prior art, the invention has the following beneficial effects:
the invention combines the traditional theory and the modern research, selects the codonopsis pilosula, the fried bighead atractylodes rhizome, the fried malt, the dried orange peel, the dried ginger, the brewing yeast powder and the hawthorn pulp powder as the raw materials, has homology of medicine and food, and has high edible safety. Experiments prove that the components have synergistic interaction, the stomach digestion is effectively promoted, the intestinal flora is adjusted, the constipation problem caused by food retention is improved, and the intestines and the stomach are simultaneously conditioned.
Detailed Description
The present invention is further illustrated by the following specific embodiments, which are not intended to limit the scope of the invention.
The raw materials adopted in the embodiment of the invention are all from commercial products.
Example 1: efficacy test
1.1 test groups are shown in Table 1:
table 1: combination 1-combination 6 formula
2.2 Effect test:
2.2.1 test methods
The test was conducted on the animal body weight, body weight gain, food intake and food utilization rate, small intestine exercise test, and digestive enzyme assay in accordance with "test for digestive function promotion test method" in "test and evaluation of health food" (2003 edition).
2.2.1.1 dose selection
The dose is calculated as 60kg for adult human body weight, 1200 mg/tablet, 2 times a day, 3 tablets each time, and is converted to 120mg/kg BW according to the recommended human body dosage of the sample. 2400mg/kg BW (equivalent to 20 times of the recommended dose in human body) was set, a negative control group was set for the digestive enzyme assay, and a negative control group and a constipation model group (model control group) were set for the small intestine exercise test. Weighing 24.0g of each combined sample, adding pure water to 100mL, dissolving and uniformly mixing to prepare 240 mg/mL solution for rat experiments; weighing 24.0g of each combined sample, adding pure water to 200 mL, dissolving and uniformly mixing to prepare a solution with the concentration of 120 mg/mL for mouse experiments. The gavage amount of the rat is 1.0 mL/100 g BW, and the gavage amount of the mouse is 0.2 mL/100 g BW.
2.2.1.2 test procedure
Body weight, weight gain, food intake and food availability experiments: selecting rats, performing intragastric administration, measuring the weight and food intake of animals for 2 times per week, and calculating the food utilization rate.
Small intestine exercise test: mice were selected and gavaged once a day. After the experiment, the animals in each group were fasted overnight without water inhibition for 16 hours, and each combination sample solution was administered 30 minutes later, the compound diphenoxylate solution was administered 30 minutes later, and the ink was administered 30 minutes later. After 25 minutes, the animals were sacrificed and the abdominal cavity was opened, and the total length of the small intestine and the ink propulsion length were measured. And calculating the ink propelling rate.
And (3) digestive enzyme determination: rats were selected and gavaged once a day. Fasting was not prohibited for 24 hours before the end of the experiment. Gastric juice discharged within 3 hours was collected by a pyloric ligation method of ether-anesthetized rats, and the amount of gastric juice per unit time was measured. Gastric fluid was taken to calculate pepsin activity and pepsin output.
2.2.1.3 test data processing
The experimental data processing is carried out statistical processing by variance analysis; but if the experimental data has irregular variance, the statistical analysis of the rank sum test is used instead. The data of the food utilization rate and the ink propulsion rate are firstly converted according to the following formula: 
,wherein P is the food utilization rate and the ink propulsion rate, expressed in decimal, and then subjected to anova.
2.2.2 test result determination
2.2.2.1 comparing the experimental group of weight, weight gain, food intake and food utilization rate with the negative control group, the difference of any index of the three indexes of weight, weight gain and food intake is significant after statistical treatment, and the food utilization rate is not obviously reduced compared with the negative control group, so that the test result can be judged to be positive.
2.2.2.2 the small intestine movement test, on the premise that the model is established, the ink propulsion rate is increased by comparing the experimental group with the model group, the difference is significant through statistical treatment, and the test result can be judged to be positive.
2.2.2.3 compared with the negative control group, the test group for digestive enzyme has increased index of gastric fluid volume, pepsin activity and pepsin output, and the difference is significant by statistical treatment, so that the test result is positive.
2.2.2.4 the comprehensive results show that the test is positive if any two of the weight, weight gain, food intake and food utilization rate, small intestine exercise test and digestive enzyme test are positive, and the product has digestion promoting function.
2.2.3 the results of the tests are shown in tables 2-5:
TABLE 2 weight and body weight gain test results
As can be seen from the table above, the weights of rats in the experimental groups and the negative control group are close to each other at the beginning of the experiment, and the differences are not significant (P is more than 0.05), which indicates that the weights of animals in the groups before the experiment are relatively balanced. At the end of the test, the weight gain of the rats in each formula experiment is higher than that of the negative control group, but the weight gain of the rats is not significant (P is more than 0.05) compared with that of the negative control group, which indicates that each formula has no obvious promotion effect on the weight gain of the rats.
Table 3 food intake and food utilization experimental results
As can be seen from the table above, the food intake and the food utilization rate of the rats in each formula are higher than those of the negative control group, but the difference between each dose group and the negative control group is not significant (P is more than 0.05), which indicates that each formula has no obvious influence on the food intake and the food utilization rate of the rats.
TABLE 4 digestive enzyme assay results
As can be seen from the above table: the gastric juice amount, pepsin activity and pepsin output of each group of the formula are higher than those of a negative control group. The difference between the gastric juice amount, the pepsin activity and the pepsin output of the formulas 1-4 and the negative control group is not significant (P is more than 0.05). The difference between the amount of gastric juice, the activity of pepsin and the output of pepsin of the group formulas 5-6 and the negative control group is significant (P is less than 0.01). The formula 5-6 has the effects of improving the gastric juice amount, the pepsin activity and the pepsin output of rats, and the formula 6 has a better effect.
TABLE 5 results of the intestinal motility test
As can be seen from the above table: the Chinese ink propulsion rate of each group of the formula is higher than that of a model control group. Through data conversion and statistical analysis, the ink propulsion rate of the formula 1-4 has no significant difference (P is more than 0.05) with the difference of a model control group. The differences between the formulas 5-6 and the model control group are all significant (P is less than 0.01). The results show that the formula 5-6 has the function of promoting the small intestine movement of constipation mice, and the formula 6 has better effect.
2.2.4 evaluation of results
The components of the composition provided by the invention are synergistic, the pepsin activity, the gastric juice amount and the pepsin output of a rat can be improved, the small intestine movement of a constipated mouse can be promoted, and the composition has an obvious digestion promoting function.
Example 2: preparation of tablets
A tablet for promoting gastric digestion comprises the following components in parts by weight:
20 parts of codonopsis pilosula, 15 parts of fried bighead atractylodes rhizome, 15 parts of fried malt, 15 parts of dried orange peel, 7 parts of dried ginger, 5 parts of brewing yeast powder, 5 parts of hawthorn pulp powder, 5 parts of beta-cyclodextrin, 10 parts of isomaltitol, 3 parts of mannitol, 2 parts of microcrystalline cellulose, 1 part of anhydrous citric acid, 0.1 part of acesulfame potassium (acesulfame potassium), 0.0.5 parts of stevioside, 1.5 parts of crospovidone, 0.5 part of silicon dioxide and 0.5 part of magnesium stearate.
The preparation process comprises the following steps:
1) weighing: weighing the medicinal materials of codonopsis pilosula, dried orange peel, fried bighead atractylodes rhizome, fried malt and dried ginger according to the formula ratio for later use. Crushing the anhydrous citric acid, screening the crushed anhydrous citric acid by a 60-mesh screen, and weighing for later use; sieving acesulfame potassium (acesulfame potassium) and stevioside with 40 mesh sieve, and weighing; accurately weighing other materials according to the dosage of each batch for later use (the materials are agglomerated and pass through a 40-mesh screen);
2) extraction: adding the weighed medicinal materials into an extraction tank, extracting for 2 times, filtering the extract, and combining the filtrates for later use;
3) concentration: taking the filtrate extracted twice, carrying out suction filtration, and recovering and concentrating the filtrate in a single-effect external circulation concentrator after suction filtration;
4) spray drying and granulating: adding beta-cyclodextrin into the concentrated solution, uniformly mixing, heating, stirring, performing spray drying, collecting spray-dried powder, and extruding the spray-dried powder through a 20-mesh screen by using an oscillating granulator to obtain spray-dried particles;
5) total mixing: adding anhydrous citric acid, acesulfame potassium (acesulfame potassium), stevioside, crospovidone, spray-dried granules, brewing yeast powder, hawthorn pulp powder, isomalt, mannitol, microcrystalline cellulose and silicon dioxide into a mixer, mixing for 25min, then adding magnesium stearate, mixing for 8min, and discharging after mixing uniformly;
6) tabletting: 1200 mg/tablet, controlling the tablet weight range, and checking the appearance of the tablet at any time;
and (5) inspecting, bottling and warehousing.
Claims (8)
1. A composition for promoting gastric digestion comprising the components: radix Codonopsis, parched Atractylodis rhizoma, parched fructus Hordei Germinatus, pericarpium Citri Tangerinae, Zingiberis rhizoma, brewing yeast powder, and fructus crataegi slurry powder.
2. The composition for promoting gastric digestion according to claim 1, which comprises the following components in parts by weight:
10-40 parts of codonopsis pilosula, 10-40 parts of fried bighead atractylodes rhizome, 10-40 parts of fried malt, 10-40 parts of dried orange peel, 2-10 parts of dried ginger, 5-20 parts of brewing yeast powder and 5-20 parts of hawthorn pulp powder.
3. The composition for promoting gastric digestion according to claim 2, which is characterized by comprising the following components in parts by weight:
20 parts of codonopsis pilosula, 15 parts of fried bighead atractylodes rhizome, 15 parts of fried malt, 15 parts of dried orange peel, 7 parts of dried ginger, 5 parts of brewing yeast powder and 5 parts of hawthorn pulp powder.
4. Use of a composition according to any one of claims 1 to 3 in the preparation of a health product for promoting gastric digestion.
5. A health product for promoting gastric digestion, which is characterized by being prepared from the composition as claimed in any one of claims 1 to 3 and auxiliary materials acceptable in the health product.
6. The health product according to claim 5, wherein the dosage form of the health product is tablet, capsule, powder, granule, pill or oral liquid, preferably tablet.
7. The health product of claim 6, wherein the tablet comprises the following components in parts by weight:
10-40 parts of codonopsis pilosula, 10-40 parts of fried bighead atractylodes rhizome, 10-40 parts of fried malt, 10-40 parts of dried orange peel, 2-10 parts of dried ginger, 5-20 parts of brewing yeast powder, 5-20 parts of hawthorn pulp powder, 5-20 parts of beta-cyclodextrin, 20-50 parts of isomalt, 2-15 parts of mannitol, 2-15 parts of microcrystalline cellulose, 2-10 parts of anhydrous citric acid, 0.1-2 parts of acesulfame potassium, 0.1-1 part of stevioside, 2-10 parts of crospovidone, 1-5 parts of silicon dioxide and 1-5 parts of magnesium stearate.
8. The health product of claim 7, wherein the preparation method of the tablet comprises the following steps:
(1) weighing: weighing the medicinal materials of codonopsis pilosula, dried orange peel, fried bighead atractylodes rhizome, fried malt and dried ginger according to the formula ratio for later use; crushing the anhydrous citric acid, screening the crushed anhydrous citric acid by a 60-mesh screen, and weighing for later use; sieving acesulfame potassium and stevioside with a 40-mesh sieve, and weighing for later use; other materials are agglomerated and pass through a 40-mesh screen;
(2) extracting and concentrating: adding weighed medicinal materials into an extraction tank, extracting with water for 1-2 times, filtering the extractive solution, and mixing
Filtering the filtrate, taking the extracted filtrate, performing suction filtration, and recovering and concentrating the filtrate after suction filtration to obtain a concentrated solution;
(3) spray drying and granulating: adding beta-cyclodextrin into the concentrated solution, mixing, heating, stirring, spray drying, and collecting
Spraying dry powder, and passing the sprayed dry powder through a 20-mesh screen in an extrusion manner to obtain spray-dried particles;
total mixing: adding anhydrous citric acid, acesulfame potassium, stevioside, crospovidone, spray-dried granules, brewing yeast powder, hawthorn pulp powder, isomalt, mannitol, microcrystalline cellulose and silicon dioxide into a mixer, mixing for 20-30min, adding magnesium stearate, mixing for 5-10min, discharging after mixing uniformly, and tabletting to obtain the finished product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010558699.9A CN111685322A (en) | 2020-06-18 | 2020-06-18 | Composition for promoting gastric digestion and health-care product and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010558699.9A CN111685322A (en) | 2020-06-18 | 2020-06-18 | Composition for promoting gastric digestion and health-care product and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111685322A true CN111685322A (en) | 2020-09-22 |
Family
ID=72481627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010558699.9A Pending CN111685322A (en) | 2020-06-18 | 2020-06-18 | Composition for promoting gastric digestion and health-care product and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111685322A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113966843A (en) * | 2021-10-22 | 2022-01-25 | 烟台新时代健康产业有限公司 | A pollen Pini composition with digestion promoting effect, and its preparation method |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1666754A (en) * | 2004-03-09 | 2005-09-14 | 岐黄药业科技投资有限责任公司 | Semi-solid oral formulation of Chinese medicine |
| CN102948549A (en) * | 2011-08-30 | 2013-03-06 | 天津尖峰弗兰德医药科技发展有限公司 | Healthy tea with effects of tonifying spleen and promoting appetite and preparation method of healthy tea |
| CN103191332A (en) * | 2012-01-04 | 2013-07-10 | 安琪酵母股份有限公司 | Composition and health-care product with stomach-invigorating and digestion-promoting functions |
| CN104208649A (en) * | 2014-09-29 | 2014-12-17 | 洛阳御平国生物科技有限公司 | Chinese medicine for treating deficient cold of spleen and stomach |
| CN104606587A (en) * | 2014-07-07 | 2015-05-13 | 王国生 | Making method for chewable tablet promoting children digestion |
| CN105477265A (en) * | 2015-12-22 | 2016-04-13 | 周伟萌 | Stomach nourishing traditional Chinese medicine composition |
| CN105596897A (en) * | 2015-12-23 | 2016-05-25 | 百花医药集团股份有限公司 | Method for making spleen tonification preparation |
| CN110934971A (en) * | 2019-12-04 | 2020-03-31 | 江苏康缘药业股份有限公司 | Composition with digestion promoting function and preparation method and application thereof |
-
2020
- 2020-06-18 CN CN202010558699.9A patent/CN111685322A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1666754A (en) * | 2004-03-09 | 2005-09-14 | 岐黄药业科技投资有限责任公司 | Semi-solid oral formulation of Chinese medicine |
| CN102948549A (en) * | 2011-08-30 | 2013-03-06 | 天津尖峰弗兰德医药科技发展有限公司 | Healthy tea with effects of tonifying spleen and promoting appetite and preparation method of healthy tea |
| CN103191332A (en) * | 2012-01-04 | 2013-07-10 | 安琪酵母股份有限公司 | Composition and health-care product with stomach-invigorating and digestion-promoting functions |
| CN104606587A (en) * | 2014-07-07 | 2015-05-13 | 王国生 | Making method for chewable tablet promoting children digestion |
| CN104208649A (en) * | 2014-09-29 | 2014-12-17 | 洛阳御平国生物科技有限公司 | Chinese medicine for treating deficient cold of spleen and stomach |
| CN105477265A (en) * | 2015-12-22 | 2016-04-13 | 周伟萌 | Stomach nourishing traditional Chinese medicine composition |
| CN105596897A (en) * | 2015-12-23 | 2016-05-25 | 百花医药集团股份有限公司 | Method for making spleen tonification preparation |
| CN110934971A (en) * | 2019-12-04 | 2020-03-31 | 江苏康缘药业股份有限公司 | Composition with digestion promoting function and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 攸宜: "《幸福女人恋上花草茶》", 30 April 2015, 北京联合出版公司 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113966843A (en) * | 2021-10-22 | 2022-01-25 | 烟台新时代健康产业有限公司 | A pollen Pini composition with digestion promoting effect, and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100937455B1 (en) | Bowel movement promotion functional food containing psyllium seed, rice bran fermentation extracts and yeast extracts and manufacturing method thereof | |
| CN105995283A (en) | Composition capable of resisting fog and haze and nourishing lung, beverage capable of resisting fog and haze and nourishing lung and preparation method of beverage | |
| CN103520577A (en) | Medicine-and-food dual-purpose preparation for treating pneumoconiosis, clearing away lung-heat and nourishing heart and preparation method for medicine-and-food dual-purpose preparation | |
| CN103191332A (en) | Composition and health-care product with stomach-invigorating and digestion-promoting functions | |
| CN107518260A (en) | A kind of food and preparation method thereof | |
| CN110051815A (en) | A kind of auxiliary hyperglycemic food ball and preparation method thereof | |
| CN112006137A (en) | Spleen-tonifying and stomach-nourishing Su-radish tea and preparation method thereof | |
| CN106723015A (en) | A kind of health food and its preparation technology with antifatigue and anti-oxidation function | |
| CN101507800A (en) | Ludisia discolor and pumpkin composite health care product capable of reducing blood sugar and preparation method thereof | |
| CN111685322A (en) | Composition for promoting gastric digestion and health-care product and application thereof | |
| CN104127823A (en) | Traditional Chinese medicine composition for treating infantile malnutrition and anorexia and preparation thereof | |
| CN1561773A (en) | Lung clearing tea | |
| CN107375509B (en) | Health food for improving immunity | |
| CN104958636A (en) | Medicinal composition for treating functional dyspepsia and preparation method of medicinal composition | |
| CN104825821A (en) | Medicine for treating diabetes and preparation method thereof | |
| CN1224354C (en) | Preparation method for health food compounded by Asparagus sprengreri, ginseng fibrous root, lily bulb and officinal dendrobium stem | |
| CN104825750B (en) | The preparation of a kind of Flos Ginseng processed and preparation method | |
| CN103720808B (en) | A kind of composition and use thereof, preparation method with relieving constipation effect | |
| CN103719863B (en) | Preparation method of red ginseng chewable tablets | |
| CN112914009A (en) | Health-care solid beverage for yang-deficiency constitution and preparation method thereof | |
| CN102485263B (en) | Medicinal composition for treating chronic cough of children and its preparation method | |
| CN112914010A (en) | Phlegm-dampness constitution health-care solid beverage and preparation method thereof | |
| CN104352802A (en) | Traditional Chinese medicine composition for treating chronic dysentery and preparation method thereof | |
| CN104547383A (en) | Traditional Chinese medicine preparation for treating liver depression food damage type postpartum food damage and preparation method thereof | |
| CN109984342B (en) | Medicated diet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200922 |
|
| RJ01 | Rejection of invention patent application after publication |